WallStreetZenWallStreetZen

NASDAQ: SGMO
Sangamo Therapeutics Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

SGMO past revenue growth

How has SGMO's revenue growth performed historically?
Company
58.34%
Industry
145.73%
Market
17.2%
SGMO's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
SGMO's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
SGMO's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

SGMO earnings and revenue history

Current Revenue
$176.2M
Current Earnings
-$257.8M
Current Profit Margin
-146.3%

SGMO Return on Equity

Current Company
-131%
Current Industry
-63.5%
Current Market
188%
SGMO's Return on Equity (-131%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when SGMO announces earnings.

SGMO Return on Assets

Current Company
-89.6%
Current Industry
2.9%
SGMO is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

SGMO Return on Capital Employed

Current Company
-223.58%
Current Industry
19.5%
SGMO's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

SGMO vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
SGMO$176.23M-$240.71M-$257.83M+15.85%N/A
GNLX$170.00k-$27.63M-$28.30M-98.46%N/A
QTTB$1.16M-$110.32M-$112.96M-26.32%N/A
ALLK$0.00-$188.42M-$185.70MN/AN/A
BYSI$1.55MN/A-$27.51M+34.56%N/A
View Top Biotech Stocks

Sangamo Therapeutics Earnings & Revenue FAQ

What were SGMO's earnings last quarter?

On Invalid Date, Sangamo Therapeutics (NASDAQ: SGMO) reported Q4 2023 earnings per share (EPS) of -$0.34, up 6.25% year over year. Total Sangamo Therapeutics earnings for the quarter were -$60.30 million. In the same quarter last year, Sangamo Therapeutics's earnings per share (EPS) was -$0.32.

If you're new to stock investing, here's how to buy Sangamo Therapeutics stock.

What was SGMO's earnings growth in the past year?

As of Q2 2024, Sangamo Therapeutics's earnings has grown year over year. Sangamo Therapeutics's earnings in the past year totalled -$257.83 million.

What was SGMO's revenue last quarter?

On Invalid Date, Sangamo Therapeutics (NASDAQ: SGMO) reported Q4 2023 revenue of $2.04 million up 92.5% year over year. In the same quarter last year, Sangamo Therapeutics's revenue was $27.23 million.

What was SGMO's revenue growth in the past year?

As of Q2 2024, Sangamo Therapeutics's revenue has grown 58.34% year over year. This is 87.39 percentage points lower than the US Biotechnology industry revenue growth rate of 145.73%. Sangamo Therapeutics's revenue in the past year totalled $176.23 million.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.